Core Insights - QuidelOrtho Corporation (QDEL) reported adjusted earnings per share (EPS) of 46 cents for Q4 2025, a decrease from 63 cents year-over-year, but exceeded the Zacks Consensus Estimate by 6.9% [1] - The company registered revenues of $723.6 million in Q4 2025, reflecting a 2.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.6% [2] Financial Performance - The GAAP loss per share for Q4 was $1.92, an improvement from a loss of $2.65 in the same quarter last year [1] - Adjusted gross profit declined 1.8% year-over-year to $325.2 million, with an adjusted gross margin contracting by 190 basis points to 44.9% [9] - Adjusted operating profit totaled $89.3 million, down 8.7% from the prior-year quarter, with an adjusted operating margin of 12.3%, a contraction of 150 basis points [10] Revenue Breakdown - Respiratory revenues were $123.3 million, down 13.9% year-over-year, while Non-Respiratory revenues increased to $600.3 million, up 6.3% [2] - Labs revenues reached $389.2 million, an 8.1% increase, while Immunohematology revenues were $141 million, up 3.4% [3][4] - Donor Screening revenues fell significantly to $11.8 million, down 40.1%, and Point of Care revenues declined to $173.1 million, down 6.4% [4] Geographical Performance - North America revenues were $390.1 million, reflecting a decline of 2.4%, while EMEA revenues increased by 9.3% to $92.7 million [6] - Revenues from China amounted to $91.7 million, up 5.5%, and Latin America revenues increased by 22% to $73.2 million [8] Future Guidance - For 2026, QuidelOrtho expects total revenues to be in the range of $2.7 billion to $2.9 billion, with a consensus estimate of $2.71 billion [12] - The company anticipates steady growth in its core Labs business and low-single-digit growth in Immunohematology, while Point-of-Care revenues are expected to remain flat [13][14]